Vanguard Investments Australia
ARQT icon

Vanguard Investments Australia’s Arcutis Biotherapeutics ARQT Stock Holding History

Vanguard Investments Australia’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$737K Hold
28,101
– – ﹤0.01% 1460
2026
Q1 		$662K Buy
+28,101
New +$717K ﹤0.01% 1441

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Investments Australia's ARQT Position: Q2 2026 in Review

Vanguard Investments Australia held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 28,101 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Vanguard Investments Australia first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Vanguard Investments Australia held 28,101 shares of Arcutis Biotherapeutics worth $737K as of Q2 2026.
  • Vanguard Investments Australia left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1460 holding.
  • Vanguard Investments Australia first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.